Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026

Reports
Published
Number of pages
1500

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$3000
CD-ROM Mail Delivery
$3600
Hard Copy Mail Delivery
$4800
Electronic Access - Multi-User License
$5100

“Global Peptide Therapeutics Market  & Clinical Pipeline Insight 2026” report highlights: 

  • Global Peptide Therapeutics Market Opportunity: US$ 65 Billion
  • Peptide Therapeutics Market Opportunity: US$ 22 Billion
  • Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs
  • Clinical & Patent Insight on 197 Marketed Peptides
  • Peptide Clinical Pipeline Is Dominated by Cyclic Peptides:  46 Peptides
  • Peptides Clinical Trials Insight by Phase, Indication & Company
  • Future Peptide Therapeutics Market Outlook

 

“Global Peptide Therapeutics Market  & Clinical Pipeline Insight 2026” report gives comprehensive insight on clinical and non-clinical parameters involved in the development of global peptide drug market.  As per report findings, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. Currently, there are more than 800 peptide drugs in clinical pipeline and 197 peptide based drugs commercially available in the market.

 

\"Oncology Segment Will Continue To Dominate The Global Peptide Therapeutics Market  In Terms Of Revenue Opportunity & Clinical Pipeline\"

 

From the last several decades, therapeutic peptides and proteins have risen as potential drug candidate. Many companies are specializing in their manufacture, along with companies developing peptide based products ranging from new drug candidates to medical diagnostic devices. The massive increase in the cost and time span to develop a conventional drugs led researchers and pharmaceutical companies to develop new cost effective products based of synthetic peptide strategy, which led to development large number of peptides of medical importance.

 

The lower toxicity levels of peptides can be credited to both their lower instance of interaction with other molecules not of interest and also to their ease of metabolism into their component amino acid residues. Pharmaceutical companies are attracted towards the peptides due to ease of manufacturing. In contrast to the old trial and error routines, nowadays the process starts with a clear understanding of the disease on a molecular level and based over the hypotheses of drug outcome, new drugs are designed.

 

The necessity of peptides as new innovative drug development has also been raised by the property of peptides being bioactive as considered one of the major interests of pharmaceuticals. As compared to synthetic substances peptides degrade into their component proteinogenic amino acid without leading to toxic metabolites. Furthermore, a disadvantage can sometimes be an advantage as peptides possess short half-lives which make them costly on one hand but advantage is less accumulation in the body.

 

\"Global Peptide Drug Market Is Projected To Surpass US$ 60 Billion By 2026 Driven By Strong Clinical Pipeline & Favorable Commercialization Parameters \"

 

In reference to these favorable attributes peptide drug market is flourishing and several peptide based therapeutics have been commercialized. With enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug. Peptide therapeutics is completely different from the traditional way and may open a new window for finding completely new peptide drugs. Also, bioinformatics and systematic biological approaches help in searching for potential peptide drug candidates based on the knowledge and data.

 

The future potential of expanding peptide therapeutic market is contributed towards the characteristics like safety, targeted drug delivery and high specificity. Especially for illnesses requiring prolonged therapy, peptides have a competitive advantage over conventional small molecule drugs. Due to their extremely high specificity for their intended target, in combination with the fact that they are extra cellularly active, much lower amounts can be formulated.

1. Introduction to Peptide Therapeutics

  1.1 Overview & Historical Development

  1.2 Why We Need Peptide Therapeutics?

 

2. Foundation of Peptide Therapeutics

  2.1 Screening of Novel Peptide Molecules

  2.2 Production of Therapeutic Peptides

  2.3 Regulation over Peptide Therapeutics

 

3. Key Aspects in Peptide Drug Development

  3.1 Approaches to Overcome Peptide Associated Limitations

    3.1.1 Terminal Protection

    3.1.2 Non-Chemical Modifications

    3.1.3 Synthetic Amino Acid Substitution & Backbone Modification

    3.1.4 Computational Modifications for Improving Aqueous Solubility & Membrane  

             Permeability

  3.2 High-Throughput Screening (HTS) for New Peptide Entity

 

4. Peptide Therapeutics over Traditional Molecules

  4.1 Peptides v/s Biological Proteins

  4.2 Peptides v/s Small Molecules

 

5. Global Peptide Therapeutics Market Scenario

  5.1 Market Overview

  5.2 Market by Region

    5.2.1 North America

    5.2.2 Europe

    5.2.3 Asia

  5.3 Peptide Therapeutic Market Segmentation by Application

    5.3.1 Peptides in Imaging

    5.3.2 Peptides in Diseases

    5.4 Market by Route of Administration

    5.4.1 Current Scenerio

    5.4.2 Current Trends over Approved Peptide Products

 

6. Global Peptide Oncology Thereupetics Market Scenario

  6.1 Market Overview

  6.2 Peptide Oncology Drug Market - Regional Segmentation

 

7. Cancer Peptides Drug Cost, Dosage & Patent Insight

  7.1 Firmagon (Degarelix)

  7.2 Mepact (Mifamurtide)

  7.3 Zoladex (Goserelin)

  7.4 Eligard (Leuprolide)

  7.5 Lupron (Leuprolide Acetate)

  7.6 Plenaxis (Abarelix)

  7.7 Trelstar (Treptorelin)

  7.8 Decapeptyl SR (Treptorelin Acetate or Pamoate)

  7.9 Octreotide

  7.10 Sandostatin (Octeriotide Acetate)

  7.11 Velcade (bortizomib)

  7.12 Cosmegen (Dactinomycin)

  7.13 Somatuline Depot (lanreotide)

  7.14 Suprefact (Buserelin)

  7.15 Ninlaro (Ixazomib)

  7.16 Kyprolis (Carfilzomib)

  7.17 Gonax (Degarelix Acetate)

 

8. Peptide Therapeutics in  Cardiovascular Disease

  8.1 Overview to Global Cardiovascular Diseases Burden

  8.2 Peptide Drugs in Cardiovascular Diseases – Availability & Cost Analysis

  8.3 Cardiac Peptide Therapeutics – Sales Analysis

 

9. Peptide Therapeutics in  Metabolic Disorder

  9.1 Overview to Global Metabolic Disorders Burden

  9.2 Peptide Drugs for Metabolic Disorders – Availability, Cost & Dosage Analysis

  9.3 Market of Metabolic Peptides

 

 

10. Peptide Therapeutics For Infections

  10.1 Overview to Infectious Diseases

  10.2 Global - HIV Infection Burden

  10.3 Commercially Available Anti-Infective Peptide Drugs

  10.4 Anti-Infectious Peptide Drugs - Regional & Sales Analysis

 

11. Peptide Therapeutics aganist CNS Disorders

  11.1 Overview to CNS Disorders

  11.2 Approaches for Developing Neuropeptide Drugs

  11.3 Opportunities for Neuropeptide Drug Market

 

12. Global Peptides Drug Clinical Insight by Type

  12.1 Dipeptides

  12.2 Cyclic Peptides

  12.3 Depsipeptides

  12.4 Glucagon-Like Peptide

  12.5 Glycopeptides

  12.6 Insulin

  12.7 Lipopeptides

  12.8 Natriuretic Peptides

  12.9 Neuropeptides

  12.10 Oligopeptides

  12.11 Opioid Peptides

  12.12 Peptide Homone

  12.13 Peptides

  12.14 Peptide Fragments

  12.15 Peptide Vaccine

  12.16 Multiple Peptides

 

13. Global Peptide Drug Market Dynamics – Challenges & Drivers

  13.1 Global Peptide Drug Market Drivers

  13.2 Challenges for Global Peptide Drug Market

 

 

14. Global Peptide Therapeutics Market Future Panorama

  14.1 Future Trends in Peptide Therapeutics

  14.2 Peptides Therapeutics Market Opportunities

 

15. Oligopeptides Clinical Pipeline By Company, Indication & Phase

  15.1 Preclinical

  15.2 Phase-I

  15.3 Phase-I/II

  15.4 Phase-II

  15.5 Phase-III

  15.6 Preregistration

  15.7 Registered

  15.8 Marketed

 

16. Insulin Clinical Pipeline By Company, Indication & Phase

  16.1 Unknown

  16.2 Research

  16.3 Preclinical

  16.4 Clinical

  16.5 Phase-I

  16.6 Phase-I/II

  16.7 Phase-II

  16.8 Phase-II/III

  16.9 Phase-III

  16.10 Preregistration

  16.11 Registered

  16.12 Marketed

 

17. Peptide Hormone Clinical Pipeline By Company, Indication & Phase

  17.1 Unknown

  17.2 Research

  17.3 Preclinical

  17.4 Clinical

  17.5 Phase-I

  17.6 Phase-I/II

  17.7 Phase-II

  17.8 Phase-III

  17.9 Preregistration

  17.10 Marketed

 

18. Peptide Clinical Pipeline By Company, Indication & Phase

  18.1 Unknown

  18.2 Research

  18.3 Preclinical

  18.4 Clinical

  18.5 Phase-I

  18.6 Phase-I/II

  18.7 Phase-II

  18.8 Phase-II/III

  18.9 Phase-III

  18.10 Preregistration

  18.11 Registered

  18.12 Marketed

 

19. Glucagon-Like Peptide Clinical Pipeline By Company, Indication & Phase

  19.1 Preclinical

  19.2 Clinical

  19.3 Phase-I

  19.4 Phase-II

  19.5 Phase-III

  19.6 Preregistration

  19.7 Marketed

 

20. Glycopeptide Clinical Pipeline By Company, Indication & Phase

  20.1 Preclinical

  20.2 Phase-I

  20.3 Phase-I/II

  20.4 Marketed

 

21. Multiple Peptide Clinical Pipeline By Company, Indication & Phase

  21.1 Research

  21.2 Preclinical

  21.3 Phase-I

  21.4 Phase-II

  21.5 Phase-II/III

  21.6 Phase-III

  21.7 Preregistration

  21.8 Registered

  21.9 Marketed

 

22. Peptide vaccine Clinical Pipeline By Company, Indication & Phase

  22.1 Preclinical

  22.2 Phase-I

  22.3 Phase-I/II

  22.4 Phase-II

  22.5 Phase-III

  22.6 Registered

  22.7 Marketed

 

23. Cyclic Peptide Clinical Pipeline By Company, Indication & Phase

  23.1 Unknown

  23.2 Research

  23.3 Preclinical

  23.4 Phase-I

  23.5 Phase-II

  23.6 Phase-II/III

  23.7 Phase-III

  23.8 Preregistration

  23.9 Registered

  23.10 Marketed

 

 

24. Peptide Fragment Clinical Pipeline By Company, Indication & Phase

  24.1 Research

  24.2 Preclinical

  24.3 Phase-I

  24.4 Phase-I/II

  24.5 Phase-II

  24.6 Phase-II/III

  24.7 Preregistration

  24.8 Registered

  24.9 Marketed

 

25. Dipeptide Clinical Pipeline By Company, Indication & Phase

  25.1 Preclinical

  25.2 Phase-I

  25.3 Phase-I/II

  25.4 Phase-II

  25.5 Phase-III

  25.6 Registered

  25.7 Marketed

 

26. Opioid peptide Clinical Pipeline By Company, Indication & Phase

  26.1 Phase-I/II

  26.2 Phase-II

  26.3 Preregistration

  26.4 Registered

  26.5 Marketed

 

27. Depsipeptide Clinical Pipeline By Company, Indication & Phase

  27.1 Preclinical

  27.2 Phase-I

  27.3 Registered

  27.4 Marketed

 

28. Natriuretic Peptide Clinical Pipeline By Company, Indication & Phase

  28.1 Research

  28.2 Phase-II

  28.3 Phase-III

  28.4 Marketed

 

29. Neuropeptide Clinical Pipeline By Company, Indication & Phase

  29.1 Research

  29.2 Preclinical

  29.3 Phase-I

  29.4 Phase-I/II

  29.5 Phase-II

  29.6 Marketed

 

30. Pituitary Gonadotropin Clinical Pipeline By Company, Indication & Phase

  30.1 Unknown

  30.2 Preclinical

  30.3 Phase-I

  30.4 Phase-II

  30.5 Phase-III

  30.6 Marketed

 

31. Lipopeptide Clinical Pipeline By Company, Indication & Phase

  31.1 Research

  31.2 Preclinical

  31.3 Phase-II

  31.4 Phase-III

 

 

32. Peptide Aptamer Clinical Pipeline By Company, Indication & Phase

  32.1 Preclinical

  32.2 Phase-I

  32.3 Phase-I/II

  32.4 Phase-III

 

33. Competitive Landscape

  33.1 Amgen

  33.2 Amylin Pharmaceuticals

  33.3 Apitope Technology

  33.4 BioPartners

  33.5 BiondVax Pharmaceuticals Ltd

  33.6 Boehringer Ingelheim

  33.7 Circassia

  33.8 Corden Pharma (Peptisyntha)

  33.9 Eli Lily

  33.10 Galena Biopharmaceuticals

  33.11 GlaxoSmithKline

  33.12 Hyperion Therapeutics

  33.13 ImmunoCellular Therapeutics

  33.14 Ipsen

  33.15 Lonza

  33.16 Merck

  33.17 NovoNordisk

  33.18 Par Pharmaceuticals

  33.19 PeptiDream

  33.20 Roche

  33.21 Sanofi

  33.22 Tarix Pharmaceuticals

 Figure 2-1: Classification of Peptides by Sources

 Figure 2-2: Screening Approaches of Novel Therapeutics peptides

 Figure 2-3: Methods for Large Scale Production of Therapeutic Peptides

 Figure 2-4: General Concept of Manufacturing of Peptide Drugs

 Figure 2-5: Process of Peptide Therapeutics FDA Approval Path

 

Figure 3-1: Different Approaches Used for Overcoming Peptide Drugs Associated Limitations

 

Figure 4- 1: Peptides as a Cusp of Small Molecule Drug & Proteins

Figure 4- 2: Advantages of Peptide Drugs

 

Figure 5-1: Global - Imaging Technology Market by Usage (%), 2018

Figure 5-2: Healthcare Imaging Market Share by Company (%), 2018

Figure 5-3: Diagrammatic Representation of the Peptidic Probe

Figure 5-4: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species

Figure 5-5: Global - Peptide Therapeutics Market Size by Clinical Indications, 2018

Figure 5-6: Global - Insulin Market Forecast (US$ Billion) 2018 - 2026

Figure 5-7: Therapeutic Peptide Based Drugs over Route of Administration

 

Figure 6-1: Global - Peptide Therapeutics Market Forecast (US$ Billion), 2018 - 2026

Figure 6-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide

Therapeutic Market Size (US$ Billion), 2019

Figure 6-3: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026

Figure 6-4: Peptide Oncology Market – Regional Market Share (%), 2018

 

Figure 7-1: Classification of Therapeutic Peptides

Figure 7-2: Frimagon – Years of Different Patent Issue

Figure 7-3: Frimagon – Expiration Year of Different Patents

Figure 7-4: Frimagon - Cost of 80mg & 120mg Supply of Powder for Subcutaneous  Injection (US$), October’2019

Figure 7-5: Firmagon - Starting & Maintenance Dosage (mg)

Figure 7-6: Firmagon – Treatment Cost of Initial Month, Maintenance Month & Annually (US$), October’2019

Figure 7-7: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment

Figure 7-8: Germany - Mepact Full Treatment Cost for Children & Adults (US$ Millions), October’2019

Figure 7-9: Zoladex – Patent Issue & Expiration Year

Figure 7-10: Zoladex - Cost of 3.6mg & 10.8mg Implant (US$), October’2019

Figure 7-11: Zoladex – Recommended Dose for Prostate cancer Management on Monthly Basis (MG), October’2019

Figure 7-12: Zoladex – Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), October’2019

Figure 7-13: Eligard – Patent Issue & Expiration Year

Figure 7-14: Eligard - Cost of Different doses of Extended Release Subcutaneous Powder for Injection (US$), October’2019

Figure 7-15: Eligard – Recommended Dosage for Porstate Cancer on Monthly Basis (mg)

Figure 7-16: Eligard – Annual Treatment cost of Prostate Cancer using Different available Doses (US$), October’2019

Figure 7-17: Eligard – Recomended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), October’2019

Figure 7-18: Eligard – Cost Per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Dose (US$), October’2019

Figure 7-19: Lupron – Patent Issue & Expiration Year for Controlled Release Preparation

Figure 7-20: Lupron – Patent Issue & Expiration Year for Sustained Release Preparation

Figure 7-21: Lupron – Price for 7.5mg, 22.5mg, 30mg & 40mg Depot (US$), October’2019

Figure 7-22: Lupron – Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 7-23: Lupron – Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), October’2019

Figure 7-24: Lupron – Recomended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), October’2019

Figure 7-25: Lupron – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Depot (US$), October’2019

Figure 7-26: Plenaxis – Number of Recommended Doses on Monthly Basis

Figure 7-27: Plenaxis – Initial, Maintenance & Full Treatment Cost (US$), October’2019

Figure 7-28: Trelstar – Patent Issue & Expiration Year

Figure 7-29: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), October’ 2019

Figure 7-30: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg), October’2019

Figure 7-31: Trelstar – Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), October’2019

Figure 7-32: Decapeptyl SR – Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (US$), October’2019

Figure 7-33: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 7-34: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), October’2019

Figure 7-35: Octreotide - Cost of Different Commercially Available mg/ml Doses of Octreotide for 10 ml Supply (US$), October’2019

Figure 7-36: Octreotide – Average Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), October’2019

Figure 7-37: Sandostatin – Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), October’2019

Figure 7-38: Sandostatin – Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), October’2019

Figure 7-39: Sandostatin – Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), October’2019

Figure 7-40: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), October’2019

Figure 7-41: Velcade – 1st & 2nd Patent Issue & Expiration Year

Figure 7-42: Velcade – Price of 3.5mg Supply & Full Treatment Cost for Multiple myeloma (US$), October’2019

Figure 7-43: Cosmegen – Average Cost of once in 3 Week & once in 6 Week Treatment Cycle for Wilm’s Tumor using 0.5mg Powder for Injection (US$), October’2019

Figure 7-44: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Rhabdomyosarcoma (US$), October’2019

Figure 7-45: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Ewing’s Tumor (US$), October’2019

Figure 7-46: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Testicular Cancer (US$), October’2019

Figure 7-47: Cosmegen – Full Treatment Cost as Monotherapy & Combinational Therapy in Trophoblastic Disease (US$), October’2019

Figure 7-48: Cosmegen – Full Treatment Cost of Upper & lower Body Solid Tumor (US$), October’2019

Figure 7-49: Somatuline Depot – Patent Issue & Expiration Year

Figure 7-50: Somatuline Depot – Price of 60mg/0.2 ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October’2019

Figure 7-51: Somatuline Depot – Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October’2019

Figure 7-52: Somatuline Depot – Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October’2019

Figure 7-53: Somatuline Depot – Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), October’2019

Figure 7-54: Suprefact – Price of 6.3mg & 9.45mg Depot (US$), October’2019

Figure 7-55: Suprefact – Cost for a Supply of 1ml/ml Nasal Spray and Injectable solution (US$), October’2019

Figure 7-56: Suprefact Injection – Recommended Initial Dose & Final Dose For Prostate Cancer Treatment (mg/Day), October’2019

Figure 7-57: Suprefact Depot – Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg), October’2019

Figure 7-58: Suprefact Depot – Annual Prostate Cancer Treatment Cost (US$), October’2019

Figure 7-59: Ninlaro – Patent Issue & Expiration Year

Figure 7-60: Ninlaro – Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), October’2019

Figure 7-61: Ninlaro – Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week), October’2019

Figure 7-62: Ninlaro – Cost of 1 Treatment Cycle & Full Treatment Cost for Multiple Myeloma (US$), October’2019

Figure 7-63: Kyprolis – Issue & Expiration Year of Patents Assigned to Proteolix Inc.

Figure 7-64: Kyprolis – Issue & Expiration Year of Patent Assigned to Cydex Pharmaceuticals

Figure 7-65: Kyprolis – Issue & Expiration Year of Patents Assigned to Onyx Therapeutics

Figure 7-66: Kyprolis – Price of 10mg, 30mgg & 60mg Intraveneous Powder for Injection (US$), October’2019

Figure 7-67: Kyprolis – Initial Dose & Maintainence Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)

Figure 7-68: Kyprolis - Initial Dose & Maintainence Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Per Week)

Figure 7-69: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), October’2019

Figure 7-70: Gonax - Starting & Maintenance Dosage (mg)

Figure 7-71: Gonax – Treatment Cost of Initial Month, Maintenance Month & Annually (US$), October’2019

 

Figure 8-1: Global - Cardiovascular Mortality (%), 2018

Figure 8-2: Cardiovascular Peptide Therapeutics - Cost Analysis (US$//Patient), 2018

Figure 8-3: Global - Angiomax Sales (US$ Million), 2018

Figure 8-4: Global - Integrilin Sales (US$ Million), 2016 & 2017

 

Figure 9-1: Global - Prevalence of Metabolic Disorders by Region (%), 2018

Figure 9-2: Layout of Metabolic Syndrome Leading to Several Diseases

Figure 9-3: Global - Top 10 Countries with Diabetes Burden (Million), 2030

Figure 9-4: Global – Obesity in Women & Men by Region (Million), 2018

Figure 9-5: US– GLP-1 Agonist Drugs Comparative Cost Analysis (US$), 2018

Figure 9-6: Lantus – Monthly Cost Comparison by Country (US$), 2018

Figure 9-7: Global – Metabolic Peptide Market Size (%), 2018

 

Figure 10-1: Global - Top 10 Leading Causes of Death

Figure 10-2: Global – Distribution of AIDS Affected Patients by Region (%), 2018

Figure 10-3: Fuzeon - Global Sales (US$ Millions), 2015 - 2017

 

Figure 11-1: US - Prevalence of Alzheimer’s disease (Million)

Figure 11-2: Alzheimer Disease Market Size (%), 2018

 

Figure 12-1: Global - Total Peptides Clinical Pipeline by Phase (%), 2018 till 2024

Figure 12-2: Global Total Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 12-3: Global - Dipeptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-4: Global - Dipeptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-5: Global - Cyclic Peptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-6: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-7: Global - Depsipeptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-8: Global - Depsipeptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-9: Global - Glucagon-Like Peptide Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-10: Global - Glucagon-Like Peptide Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-11: Global - Glycopeptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-12: Global - Glycopeptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-13: Global - Insulin Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-14: Global - Insulin Clinical Pipeline by Phase (%), 2019 till 2026

Figure 12-15: Global - Lipopeptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-16: Global - Lipopeptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-17: Global - Natriuretic Peptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-18: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-19: Global - Neuropeptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-20: Global - Neuropeptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-21: Global - Oligopeptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-22: Global - Oligopeptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-23: Global - Opioid Peptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-24: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-25: Global - Peptide Hormone  Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-26: Global - Peptide Hormone  Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-27: Global - Peptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-28: Global - Peptides Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-29: Global - Peptide Fragments Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-30: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-31: Global - Peptide Vaccine Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-32: Global - Peptide Vaccine Clinical Pipeline by Phase (Number), 2019 till 2026

Figure 12-33: Global - Multiple Peptides Clinical Pipeline by Phase (%),2019 till 2026

Figure 12-34: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2019 till 2026

 

Figure 13-1: Illustration of Peptide Therapeutics Market Drivers

Figure 13-2: Major Challenges Faced by the Peptide Therapeutics

 

Figure 14-1: Global – Estimated Future Peptide Therapeutics Market Size by Clinical Indication (%), 2026

Figure 14-2: Global - Cancer Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024

Figure 14-3: Global - Metabolic Disorders Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024

Figure 14-4: Global - Cardiovascular Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024

Figure 14-5: Global - CNS, HIV & Infection Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024

Figure 14-6: Future Trends of Peptide Therapeutics

 

 

List of Tables

 

Table 4-1: Comparative Differentiation between Peptide & Protein Drugs

Table 4-2: Comparative Analysis of Small Molecules & Peptide Drugs

Table 5-1: List of Approved Peptide Drugs Since 2000

Table 7-1: Peptide Based Drugs

Table 8-1: Approved Peptide Drugs for Cardiovascular Diseases

Table 9-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders

Table 9-2: Layout of Insulin & its Analogs Cost in US

Table 10-1: Approved Drugs for Infections

Table 11-1: Brief Characterization of Some Neuroprotective Peptides

Table 11-2: Potential Targets for Peptide Based Therapies in CNS Disorders